The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma
暂无分享,去创建一个
James R. Anderson | D. Rodeberg | S. Spunt | D. Hawkins | W. Meyer | T. Yock | L. Teot | D. Parham | B. Shulkin | Yueh-Yun Chi | Jing Tian | S. Malempati | B. Weigel